Ionis Pharmaceuticals (IONS)
(Real Time Quote from BATS)
$47.17 USD
+0.11 (0.23%)
Updated Aug 13, 2024 12:02 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IONS 47.17 +0.11(0.23%)
Will IONS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IONS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IONS
The Zacks Analyst Blog AstraZeneca, Ionis and Sanofi
How Should You Play AstraZeneca (ABBV) After Q2 Beat, View Raise?
IONS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises
Ionis Pharmaceuticals (IONS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates
Other News for IONS
Tweedy Browne Amplifies Stake in CNH Industrial NV by Over 1300%
Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value
ClearBridge All Cap Growth Strategy Q2 2024 Commentary
Insider Sale at Ionis Pharmaceuticals Inc (IONS) by EVP, Chief Development Officer Richard Geary
Canaccord reiterates Buy rating on Clene following 'intriguing' new data